Literature DB >> 15195897

Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma.

Sang Hyo Shin1, Young-Hwa Chung, Dong Dae Suh, Jung Woo Shin, Myoung Kuk Jang, Soo Hyung Ryu, Neung Hwa Park, Han Chu Lee, Yung Sang Lee, Dong Jin Suh.   

Abstract

OBJECTIVE: Budd-Chiari syndrome (BCS) is a known risk factor for hepatocellular carcinoma (HCC). Considering the pathophysiological mechanism of BCS, BCS-associated HCC may have a different carcinogenic process to hepatitis B virus (HBV)-associated HCC, resulting in different characteristic clinical features.
METHODS: The clinical, radiological and histopathological characteristics of 15 HCCs associated with BCS were analysed and compared with 211 HBV-associated HCCs.
RESULTS: HCC associated with BCS showed a female predominance in contrast to a male predominance in HCC associated with HBV infection. Child classes of BCS-associated HCC patients were not different from the classes of HBV-associated HCC. BCS tended to be associated with the single nodular type of HCC. Only one BCS-associated HCC patient had portal vein invasion at the time of diagnosis, compared with 96 patients with HBV-associated HCC. No HCC patients with BCS showed biliary invasion, compared with 47 HBV-associated HCC patients. The median survival period of HCC patients associated with BCS was 58 months, which was much longer than the median survival period of 10 months in HBV-associated HCC. All of the three BCS-associated HCCs available for histological examination were well differentiated.
CONCLUSIONS: Patients with HCC associated with BCS seemed to survive for much longer periods than those with HBV due to the low invasiveness of the tumour. Such unique clinical features may be evidence of different carcinogenic processes in BCS-associated and HBV-associated HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195897     DOI: 10.1097/00042737-200403000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Authors:  Xiaowei Dang; Luhao Li; Suxin Li; Yafei Wang; Hai Li; Shaokai Xu; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Liver cirrhosis in hepatic vena cava syndrome (or membranous obstruction of inferior vena cava).

Authors:  Santosh Man Shrestha
Journal:  World J Hepatol       Date:  2015-04-28

Review 3.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

4.  Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea.

Authors:  Hana Park; Jin Young Yoon; Kyeong Hye Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

Review 5.  Budd-Chiari syndrome.

Authors:  Pieter Martens; Frederik Nevens
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

6.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

7.  Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization.

Authors:  Feng-Yong Liu; Mao-Qiang Wang; Feng Duan; Qing-Sheng Fan; Peng Song; Yan Wang
Journal:  BMC Gastroenterol       Date:  2013-06-24       Impact factor: 3.067

8.  Combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular subtype after inferior vena cava stent placement for a patient with Budd-Chiari syndrome.

Authors:  Makoto Sakane; Keigo Osuga; Takahiro Matsui; Hidetoshi Eguchi; Masatoshi Hori; Noriyuki Tomiyama
Journal:  Acta Radiol Open       Date:  2016-11-22

9.  Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome.

Authors:  Morgane Van Wettere; Luisa Paulatto; Lucas Raynaud; Onorina Bruno; Audrey Payancé; Aurélie Plessier; Pierre-Emmanuel Rautou; Valérie Paradis; Dominique Cazals-Hatem; Dominique Valla; Valérie Vilgrain; Maxime Ronot
Journal:  JHEP Rep       Date:  2020-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.